Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; lactose monohydrate; magnesium stearate; disodium edetate; sodium starch glycollate; guar gum; colloidal anhydrous silica; ethylcellulose - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate; ethylcellulose; colloidal anhydrous silica; guar gum; magnesium stearate; disodium edetate - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - nystatin, quantity: 500000 iu - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; ethanol; iron oxide yellow; titanium dioxide; gelatin; isopropyl alcohol; shellac; carbon black - indications as at 24 may 2005 : nilstat oral is indicated for the treatment of intestinal candidiasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - nystatin, quantity: 500000 iu - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate; ethylcellulose; purified water; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - indications as at 24 may 2005 : intestinal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg; fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg fluconazole 150mg - canesten fluconazole capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-17823 sodium laurilsulfate titanium dioxide water - canesten fluconazole capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg; clotrimazole 10 mg/g; clotrimazole 10 mg/g; fluconazole 150mg - combination - active: fluconazole 150mg clotrimazole 10 mg/g excipient: benzyl alcohol cetostearyl alcohol cetyl palmitate octyldodecanol polysorbate 60 purified water sorbitan stearate active: clotrimazole 10 mg/g excipient: benzyl alcohol cetostearyl alcohol cetyl palmitate octyldodecanol polysorbate 60 purified water sorbitan stearate active: fluconazole 150mg - canesten fluconazole capsule & clotrimazole cream duo is indicated for vaginal candidiasis. the cream can also be used for relief of external itching/irritation and the management candida vulvovaginitis or infection of the peri-anal area.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - miconazole nitrate 2%{relative} - vaginal cream - 2 % - active: miconazole nitrate 2%{relative} excipient: benzyl alcohol cetostearyl alcohol cetyl esters wax octyldodecanol polysorbate 60 purified water sorbitan stearate - local treatment of vulvovaginal candidiasis and superinfections due to gram-positive bacteria. micreme vaginal cream may also be used for the treatment of mycotic balanitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - nystatin 500000 [iu];  ;  ;   - capsule - 500000 iu - active: nystatin 500000 [iu]       excipient: lactose monohydrate magnesium stearate - nilstat capsules are indicated for the treatment of intestinal candidiasis caused by candida albicans.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ivermectin 3mg - tablet - 3 mg - active: ivermectin 3mg excipient: butylated hydroxyanisole citric acid magnesium stearate microcrystalline cellulose starch - · treatment of intestinal strongyloidiasis (anguillulosis). · treatment of proven suspected microfilaraemia in patients with lymphatic filariasis caused by wuchereria bancrofti. · treatment of human sarcoptic scabies after prior treatment has failed. treatment is justified when the diagnosis of scabies has been established clinically and/or by parasitological examination. without formal diagnosis, treatment is not justified in case of pruritus.